Drugs / LMP2 CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00062868 | Sep 2003 → Apr 2014 | Hodgkins lymphoma, leiomyosarcoma, lymphoepithelial-like carcinoma, non-Hodgkin lymphoma | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP2 CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00062868 ↗ |
| Modality | Cell therapy | “we will generate autologous (or syngeneic) or allogeneic LMP2A-specific cytotoxic T-cells and adoptively transfer them to patients” NCT00062868 ↗ |
| Route | Other | “the cells will then be thawed and injected into the patient over 10 minutes” NCT00062868 ↗ |